The global central nervous system biomarker discovery, drug development, and then molecular diagnostics segments represent 15.1 % (nearly $2 billion) of the total biomarker sector, estimated at $13.2 billion in 2012. The worldwide market for those biomarkers is projected how to have a strong pelvic floor (find more) grow to more than $32.1 billion by 2017, and the CNS biomarker segment is anticipated to achieve $5.1 billion, boosting its market share to 16.1 % of the whole market for biomarkers.
The projected advancement of CNS biomarkers revenue is dependant on the projection that a number of CNS biomarkers in the early stages of development will effectively finish their assessment and validation and obtain FDA approval throughout the forecast period of 2012 to 2017.
The CNS molecular diagnostic industry is expected to see the greatest development, increasing from $196 million in 2012 to nearly $1.5 billion by 2017 at a CAGR of 49.6 %. This kind of big increase is because of the number of diagnostic exams that are in business pipelines. Tests for Alzheimer’s disease, schizophrenia, and a number of sclerosis are expected to be commercialized within the next couple of years. These disorders represent huge markets and also have unmet needs in both diagnosis and treatment.
Growth in the global central nervous system biomarker industry for drug development continues to be modest in the years before 2012. As much more validated biomarkers start to be for patient segmentation and assessment of efficacy for medical trials, this particular current market will begin to exhibit considerable development during the five-year forecast period. Revenues from this segment in 2012 are projected at $194 million and are likely to increase to $776 million by 2017, a CAGR of thirty two %.
The discovery portion of the CNS biomarker sector will exhibit modest growth throughout the next 5 years, in part because a lot of the proteins involved in the main CNS disease pathways are found. New discoveries are likely down the road, however, as proteomics analysis advances. Projected revenues for CNS biomarker finding in 2012 were nearly $1.6 billion, and this’s anticipated to increase to about $2.9 billion by the tail end of 2017 at a CAGR of 12.3 %.
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets (BIO074B) will assist its readers:
• Assess the various technologies used for CNS biomarker discovery and future diagnostics
• Understand the process of CNS biomarker development from discovery to commercialization and the path toward adoption
• Examine the regulatory landscape as well as government’s role
• Examine the succeeding advances that need being made in the diagnosis as well as treatment of various CNS conditions • Determine current and future CNS biomarker marketplaces.
